Maintaining sterility is a costly process for drug manufacturers,
but US company Pall Corp says it has introduced a new device that
will allow biopharmaceutical producers to make aseptic connections
instantly, reaping large savings...
Scientists in Australia report this week that they have developed a
powerful software modelling tool, MolSAR, which could have the
potential to reduce drug development costs by up to €28 million per
Dharmacon, a US supplier of RNA and RNA-interference research
products, announced today it has launched Cell Cycle siARRAY, a
collection of ready-to-use siRNA duplexes designed to knock down
112 genes involved in cell cycle regulation.
A series of new flow cytometry products will soon hit the market
with the announcement yesterday from US companies BD Biosciences
and Molecular Probes that, following a recent license agreement, BD
Biosciences Pharmingen has launched...
For years, it has been common wisdom in the pharmaceutical industry
that delivery of drugs via the nose only really works if the
compound can be presented in liquid form. One company begging to
differ is Britannia Pharmaceuticals...
In the second mass spectrometer news of the week, life science
product company Agilent Technologies has introduced an ion trap
mass spectrometer that is approximately 10 times more sensitive
than its predecessor, the company claims.
Amersham Biosciences has launched a new bench-top separations
system for purifying proteins, äKTApilot, which for the first time
allows scientists to carry out process development right through to
small-scale production using a single...
UK microbial testing company Celsis International announced this
week that food giant Nestle has selected Celsis' recently launched
milk and cream diagnostic system for its global Research &
Development site in Konolfingen.
Amarin corporation this week confirmed that its Swedish subsidiary
Amarin Development AB, as part of an agreement with Watson
Pharmaceuticals, has developed a generic formulation of glipizide
extended release tablets.